Annetine Gelijns, PhD, Has Been Appointed Chair of the Department of Health Evidence and Policy at The Mount Sinai Medical Center

Dr. Gelijns arrived in 2008 as part of an extraordinary health outcomes research and policy team.

New York
 – November 27, 2012 /Press Release/  –– 

Annetine Gelijns, PhD, an internationally recognized expert in health policy and clinical evaluative research, has been named Chair of the Department of Health Evidence and Policy at Mount Sinai School of Medicine. The appointment is effective immediately.

"Dr. Gelijin's cutting-edge work provides critical insight into the forces that drive the rate and direction of technological change in medicine that promises to improve patient outcomes and reduce health care costs," said Dennis Charney, MD, the Anne and Joel Ehrenkranz Dean of Mount Sinai School of Medicine and Executive Vice President for Academic Affairs of The Mount Sinai Medical Center. "As Department Chair, Dr. Gelijns will lead Health Evidence and Policy forward in pursuing innovative research across the full spectrum of translational research—from first in-human studies to comparative effectiveness research and implementation science—and in exploring their policy implications for improving the quality, equity, and affordability of health care."

Dr. Gelijns was recruited to Mount Sinai School of Medicine in 2008 as part of an extraordinary health outcomes research and policy team.  Eric A. Rose, MD, was recruited as Chair, along with Dr. Gelijns and Alan Moskowitz , MD, as Co-Chairs.  Together they have invigorated the Department of Health Evidence and Policy with greatly expanded research programs.  Dr. Gelijns' own research focuses on surgical and device-based trials; comparative effectiveness research; and the factors shaping the development and diffusion of medical technology, and their policy implications.  She has written extensively about the uncertainty involved in medical research, the roles of the public and private sectors in technological change, and the dynamics of pharmacological, device, and surgical innovation.

Dr. Gelijns' recent work has focused on the design, execution, and policy implications of clinical trials of novel surgical procedures, biologicals (including stem-cell therapies), and implantable devices.  She directed the Data Coordinating Center (DCC) for the landmark REMATCH (Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure) trial that established for the first time the survival and quality-of-life benefit of long-term implanted mechanical circulatory support devices for patients with advanced heart failure.  Dr. Gelijns has extended this work by co-directing the DCC for a Specialized Centers of Clinically Oriented Research grant, funded by the National Institutes of Health, that coordinated a host of ongoing trials exploring the human biology of long-term mechanical circulatory support.  She is currently the joint PI of the DCC for the Cardiothoracic Surgical Trials Network, which is funded by the National Heart, Lung and Blood Institute, the National Institute of Neurological Disorders and Stroke, and the Canadian Institute of Health Research.

Dr. Gelijns received her LLM from the University of Leyden in the Netherlands and earned her PhD at the University of Amsterdam School of Medicine.  Following early career roles at the Steering Committee on Future Health Scenarios (co-sponsored by the World Health Organization and the Dutch Government) and the Institute of Medicine of the National Academy of Sciences, Dr. Gelijns joined the faculty of Columbia University, with appointments in both the School of Public Health and the School of Medicine.  While at Columbia, she founded and co-directed, with Dr. Moskowitz, the International Center for Health Outcomes and Innovation Research (InCHOIR), which, now at Mount Sinai, continues to lead efforts in multi-center clinical trials.

Additionally, Dr. Gelijns has served as a consultant to various national and international organizations, including the Organization for Economic Cooperation and Development in France and the National Academy of Engineering and the Institute of Medicine.  She was also a member of the board of the International Society on Technology Assessment in Health Care.

About The Mount Sinai Medical Center

The Mount Sinai Medical Center encompasses both The Mount Sinai Hospital and Mount Sinai School of Medicine. Established in 1968, Mount Sinai School of Medicine is one of the leading medical schools in the United States. The Medical School is noted for innovation in education, biomedical research, clinical care delivery, and local and global community service. It has more than 3,400 faculty in 32 departments and 14 research institutes, and ranks among the top 20 medical schools both in National Institutes of Health (NIH) funding and by U.S. News & World Report.

The Mount Sinai Hospital, founded in 1852, is a 1,171-bed tertiary- and quaternary-care teaching facility and one of the nation's oldest, largest and most-respected voluntary hospitals. In 2012, U.S. News & World Report ranked The Mount Sinai Hospital 14th on its elite Honor Roll of the nation's top hospitals based on reputation, safety, and other patient-care factors. Mount Sinai is one of 12 integrated academic medical centers whose medical school ranks among the top 20 in NIH funding and U.S. News & World Report and whose hospital is on the U.S. News & World Report Honor Roll. Nearly 60,000 people were treated at Mount Sinai as inpatients last year, and approximately 560,000 outpatient visits took place.

For more information, visit

Find Mount Sinai on: